67 MSEK in new funding
We are pleased to announce that we have raised SEK 67 million in a new share issue led by Sciety. Other significant investors include Karolinska Development, Polynom AB, Almi Invest, and Almi Invest Syd. The new capital will be used to finance drug substance manufacture, implement a clinical phase I trial of the drug candidate PN6047, and continue the company's development.
Per von Mentzer, CEO, comments:
"We are delighted to have secured this new capital and would like to thank everyone who has participated in the share issue for their great trust in PharmNovo. As a result, we are now well equipped to continue developing our treatment for neuropathic pain. We look forward to the first in-human-study, which is expected to start later this year."
Göran Lerenius, Chairman of the board, comments:
"This successful capital raise is proof of the great interest in our work. In addition to the capital injection, it is also very satisfying to have a group of investors with us who share our vision of improving the quality of life for the millions of people who suffer from neuropathic pain."
More information:
67 MSEK in new funding
We are pleased to announce that we have raised SEK 67 million in a new share issue led by Sciety. Other significant investors include Karolinska Development, Polynom AB, Almi Invest, and Almi Invest Syd. The new capital will be used to finance drug substance manufacture, implement a clinical phase I trial of the drug candidate PN6047, and continue the company's development.
Per von Mentzer, CEO, comments:
"We are delighted to have secured this new capital and would like to thank everyone who has participated in the share issue for their great trust in PharmNovo. As a result, we are now well equipped to continue developing our treatment for neuropathic pain. We look forward to the first in-human-study, which is expected to start later this year."
Göran Lerenius, Chairman of the board, comments:
"This successful capital raise is proof of the great interest in our work. In addition to the capital injection, it is also very satisfying to have a group of investors with us who share our vision of improving the quality of life for the millions of people who suffer from neuropathic pain."
More information:
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
